分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Targeting neddylation inhibits intravascular survival and extravasation of cancer cells to prevent lung-cancer metastasis

Jiang Yanyu, Liang Yupei, Li Lihui, Zhou Lisha, Cheng Wei, Yang Xi, Yang Xuguang, Qi Hui, Yu Jinha, Jeong Lak Shin, Hoffman Robert M., Zheng Peiyong, Jia Lijun

Journal:CELL BIOLOGY AND TOXICOLOGY

IF:5.1

DOI:10.1007/s10565-019-09472-w

PMID:31140025

Published:2019-05-28

research field:肿瘤学药理学细胞生物学

Abstract

Metastasis is the leading cause of tumor-related death from lung cancer. However, limited success has been achieved in the treatment of lung cancer metastasis due to the lack of understanding of the mechanisms that underlie the metastatic process. In this study, Lewis lung carcinoma (LLC) cells which expressed green fluorescent protein in the nucleus and red fluorescent protein in the cytoplasm were used to record metastatic process in real-time via a whole-mouse imaging system. Using this system, we show the neddylation inhibitor MLN4924 inhibits multiple steps of the metastatic process, including intravascular survival, extravasation, and formation of metastatic colonies, thus finally suppressing tumor metastasis. Mechanistically, MLN4924 efficiently inhibits the expression of MMP2, MMP9, and vimentin and disrupts the actin cytoskeleton at an early stage to impair invasive potential and subsequently causes a DNA damage response, cell cycle arrest, and apoptosis upon long exposure to MLN4924. Furthermore, MMP2 and MMP9 are overexpressed in patient lung adenocarcinoma, which conferred a worse overall survival. Together, targeting the neddylation pathway via MLN4924 suppresses multiple steps of the metastatic process, highlighting the potential therapeutic value of MLN4924 for the treatment of metastatic lung cancer.

本文使用的Yeasen产品

购物车
客服
转染试用